Overview: High-Sensitivity C-Reactive Protein (hs-CRP) Marker Rapid TestIntroduction: The High-Sensitivity C-Reactive Protein (hs-CRP) Marker Rapid Test is a diagnostic tool designed to detect hs-CRP levels in serum or whole blood samples, facilitating the screening of inflammation or cardiovascular risk. Associated with atherosclerosis or chronic inflammatory diseases, this condition presents with chest pain, fatigue, and severe complications like myocardial infarction if untreated, particularly in individuals with obesity or smoking history. Per the 2023 American Heart Association guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in cardiology or rheumatology settings. This rapid diagnostic falls under clinical pathology and targets individuals with systemic or cardiovascular symptoms, addressing the challenge of early detection to guide anti-inflammatory therapy or lifestyle changes. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: hs-CRP Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Roche, this test advanced inflammation marker detection, providing a high-sensitivity rapid alternative to traditional assays.Purpose: The test screens for hs-CRP to guide inflammation or cardiovascular risk diagnosis, assess immune status, and inform treatment and prevention strategies.Test Parameters: Presence of hs-CRP, detected with reasonable specificity to indicate inflammation, typically detectable in serum or blood at elevated levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report chest pain, fatigue, or recent infections.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on chest pain, fatigue, chronic inflammation, or prior cardiovascular issues, as well as any family history of heart disease or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated inflammation including myocardial infarction, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent surgery can affect results. Correlation with LDL or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible inflammation or cardiovascular risk, necessitating further investigation like LDL levels or cardiology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.Specialist Consultation: Cardiologists or rheumatologists should be consulted for case management, treatment planning, and coordination with disease programs.Additional Supporting Tests: LDL, ESR, or ECG for confirmation.Test Limitations: The test may produce false positives in acute infection or false negatives in chronic conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AHA Guidelines 2023, Journal of Cardiology 2024, Pathology 2025.